| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 01, 2019 | SVP and GM of Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP and GM of Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP and GM of Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP Global Operations and R&D | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | 14,090 | |
| Feb 01, 2019 | SVP Global Operations and R&D | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP Global Operations and R&D | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP Global Operations and R&D | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP Global Operations and R&D | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Jan 31, 2019 | SVP/GM, Global Vascular | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 981 | $21.10 | 16,142 | |
| Nov 07, 2018 | EVP and CFO | Form 4 | Open market or private sale of non-derivative or derivative security | 1,939 | $21.53 | 20,731 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.